Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026)
Johnson & Johnson (JNJ) posted Net Cash Flow of -$1.3 billion for Q2 2026, down 163.42% sequentially from $2.0 billion in Q1 2026, and up 93.66% YoY from -$656.3 million in Q2 2025.
Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Net Cash Flow for 18 years, with the latest figure at -$1.3 billion in Q2 2026.
- Quarterly Net Cash Flow rose 93.66% year-over-year to -$1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (up 129.29% YoY) and the FY2025 annual result came in at -$4.6 billion, down 281.34% from the prior year.
- Net Cash Flow declined to -$1.3 billion in Q2 2026 per JNJ's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Net Cash Flow peaked at $14.3 billion in Q1 2025 and troughed at -$20.1 billion in Q2 2025.
- A 5-year average of -$82.3 million and a median of -$405.0 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 414.6% in 2023, then sank 3831.57% in 2025.
- Over 5 years, Net Cash Flow stood at -$4.0 billion in 2022, then surged by 149.65% to $2.0 billion in 2023, then soared by 115.5% to $4.3 billion in 2024, then slumped by 66.34% to $1.5 billion in 2025, then sank by 187.35% to -$1.3 billion in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.3 billion, $2.0 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -1.27 Bn |
| Jun 28, 2026 | -1.27 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | -300.00 Mn |
| Sep 28, 2025 | -300.00 Mn |
| Jun 29, 2025 | -20.05 Bn |
| Jun 29, 2025 | -20.05 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Jun 30, 2024 | -510.00 Mn |
| Jun 30, 2024 | -510.00 Mn |
| Mar 31, 2024 | 3.74 Bn |
| Mar 31, 2024 | 3.74 Bn |